Oncologists Feeling the Provenge Blahs? | GenomeWeb

Investment bank R.W. Baird recently commissioned a survey of oncologists that may give biotech company Dendreon some cause for worry. The survey suggests that oncologists are feeling lukewarm about Dendreon's prostate cancer drug Provenge, and may be moving on to other treatments, reports Forbes' Matthew Herper. Baird analyst Christopher Raymond says there are three reasons why Provenge isn't as popular as it used to be.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.